Anzeige
Mehr »
Login
Dienstag, 28.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
160 Leser
Artikel bewerten:
(1)

Ashoka WhiteOak Emerging Markets Trust Plc - Quarterly Update - December 2024

Finanznachrichten News

Ashoka WhiteOak Emerging Markets Trust Plc - Quarterly Update - December 2024

PR Newswire

LONDON, United Kingdom, January 27

27 January 2025

Ashoka WhiteOak Emerging Markets Trust plc

(the 'Company')

Quarterly Update - December 2024

The Company's quarterly factsheet as at 31 December 2024 is now available: https://awemtrust.com/factsheet/

The Fund was up 2.63% in Q4 2024, outperforming the benchmark by 4.11%. The key contributors include KRN Heat Exchanger (+231.4%), DBS Group (+17.1%), and MediaTek (+24.5%), whereas Samsung Electronics (-17.1%), Nien Made (-25.7%), and Allegro.eu (-22.6%) were the key detractors.

For CY 2024, the Fund was up 14.52%, outperforming the benchmark by 5.09%. The key contributors include KRN Heat Exchanger (+231.4%), Naspers (+32.0%), and DBS Group (+50.2%), whereas Samsung Electronics (-38.4%), Raia Drogasil S.A. (-39.3%), and Budweiser Brewing (-45.6%) were the key detractors.

Market Review

In Q4 2024, MSCI EM index was down 1.5%. It underperformed other global indices like the US equities (S&P 500) and MSCI World which returned 9.5% and 6.9%, respectively. For the quarter, Information Technology and Financials outperformed, while Materials and Consumer Discretionary underperformed. Large caps underperformed mid and small caps in Q4 2024. Among major EM markets, Taiwan and Saudi Arabia outperformed, while Brazil and Indonesia underperformed.

In CY 2024, the MSCI EM index was up 9.4%. It underperformed other global indices like the US equities (S&P 500) and MSCI World which returned 26.9% and 21.0%, respectively. For the year, Information Technology and Communication Services outperformed, while Materials and Consumer Staples underperformed. Large caps underperformed mid and small caps in CY 2024. Among major EM markets, Taiwan and China outperformed, while Brazil and South Korea underperformed.

Top 10 Holdings

Top 10 holdings (as at 31 December 2024)

Country

% of NAV

  1. TSMC

Taiwan

7.5

  1. Samsung Electronics

South Korea

2.6

  1. OneSource Speciality Pharma

India

2.5

  1. Naspers

South Africa

2.2

  1. Hong Kong Exchanges & Clearing

China/HK

2.1

  1. Inventurus Knowledge Solutions

India

1.9

  1. Prosus NV

Netherlands

1.7

  1. Alibaba Group Holding

China/HK

1.5

  1. International Gemmological Institute

India

1.5

  1. SK Hynix

South Korea

1.3

Total

24.8%

Key Contributors

Q4 2024

Key Contributors

Ending

Weight (%)

Total

Return (%)

Contribution to

Return (bps)

KRN Heat Exchanger

0.6

+231.4

+321

Awfis Space Solutions

7.5

+16.6

+112

DOMS Industries

1.9

+45.2

+157

Naspers Limited

1.3

+17.1

+75

DBS Group Holdings

1.0

+24.5

+70

Key Detractors

Q4 2024

Key Detractors

Ending

Weight (%)

Total

Return (%)

Contribution to

Return (bps)

Samsung Electronics

2.6

-17.1

-58

Alibaba Group Holdings

1.5

-19.8

-39

Nien Made Enterprise

0.7

-25.7

-24

Allegro.eu SA

0.6

-22.6

-17

Cholamandalam Fin. Hold.

0.4

-28.3

-16

Source: Factset. Past performance does not predict future returns. The performance calculation is based on GBP. Currency fluctuations will also affect the value of an investment.

AboutAshoka WhiteOak Emerging Markets Trust plc

Ashoka WhiteOak Emerging Markets Trust plc (AWEMT) is a UK investment trust seeking to achieve long-term capital appreciation primarily through investing in a multi-cap portfolio of equities that provide exposure to global emerging markets. Advised by White Oak Capital Partners Pte. Ltd, founded by Prashant Khemka with leading Emerging Markets investment experience. White Oak Capital Group has delivered an exceptional track record for its other strategies, and has £6.0 billion in assets under management or advisory4. Analytical approach integral to disciplined research process underpinned by proprietary frameworks OpcoFinco for valuation and ABLEx for ESG research. The team at WhiteOak believes that emerging markets present potential for higher alpha. EM markets remain under-researched and inefficient. AWEM leverages WhiteOak's investment approach to capture the higher alpha potential in these markets. No fixed management fee. Manager remuneration is aligned with alpha generation and hence shareholders' interest. The Investment Manager is remunerated solely as a function of outperformance over the benchmark.

4 Data as at 31 December 2024. AUM data refers to aggregate assets under management or investment advisory for WhiteOak Group.

Further Information

For further information on the Company's investment strategy and portfolio construction approach as well as details of the portfolio market cap, regional and sector composition please refer to the latest factsheet.

Investment Objective

To achieve long-term capital appreciation, primarily investing in equity and equity-related securities that provide exposure to global emerging markets.

Summary of Investment Policy

The Company shall invest primarily in securities admitted to trading on any stock exchange (which may include stock exchanges in Developed Markets) that provide exposure to companies that are domiciled in Global Emerging Markets (EMs), or that are domiciled in Developed Markets but at the time of investment, derive a majority of their economic value, revenues or profits from, or whose assets or cost base are mainly located in EMs.

The Company's LEI is 254900Z4X5Y7NTODRI75

- Ends -

For further information:

Company Secretary

AWEMT.Cosec@jtcgroup.com

Tel: +44 (0) 20 7409 0181

WhiteOak Capital Partners Pte Ltd.

Prashant Khemka

Via Burson Buchanan

Fadrique Balmaseda

Ben Hayward

Marex

Mark Thompson

Tel: +44 (0) 20 7016 6711

Eddie Nissen

Tel: +44 (0) 20 7016 6713

Oliver Kenyon

Tel: +44 (0) 20 7016 6704

Burson Buchanan

Henry Harrison-Topham

Tel: +44 (0) 20 7466 5000

Henry Wilson

AWEM@buchanancomms.co.uk

Samuel Adams




© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.